MedImmune's intranasal flu vaccine FluMist receives recommendation from Advisory Committee on Immunization Practices Sept. 25 for use in healthy people ages 5 to 49 years of age. MedImmune has shipped 2.4 mil. doses to date; Wyeth's DTC ad campaign is underway (1"The Pink Sheet" Sept. 22, 2003, p. 16)...
You may also be interested in...
The initial coverage decisions for the FluMist nasal flu vaccine indicate that MedImmune and Wyeth will be able to maintain the $46 per dose price of the vaccine
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.